Please ensure Javascript is enabled for purposes of website accessibility

Marking the Way for Alzheimer's Drugs

By Dave Williamson - Apr 19, 2013 at 5:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Can Eli Lilly crack the Alzheimer's code?

Editor's note: An earlier version of this article incorrectly stated that Eli Lilly purchased two companies from Siemens. The actual transaction was for two tracers used in detecting tau tangles. The video also misidentifies a collaboration between Eli Lilly and General Electric for similar diagnostic products. GE Healthcare is developing a tau tangle imaging test that is independent of Eli Lilly. The Fool regrets the error.

In this video, health care analyst David Williamson discusses Eli Lilly's (LLY 1.62%) recent purchase of two imaging tracers from German conglomerate Siemens. The big pharma currently has Amyvid approved, which detects amyloid brain plaques. Like Amyvid, Eli Lilly is hoping that these tau tangle diagnostics will help both with detection and potentially serve as markers for treatment. Watch and find out how the treatment for Alzheimer's disease is evolving and some potentially groundbreaking drugs in the pipeline.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$303.68 (1.62%) $4.83
General Electric Company Stock Quote
General Electric Company
GE
$76.20 (1.26%) $0.95
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$94.78 (1.31%) $1.23
Siemens Aktiengesellschaft Stock Quote
Siemens Aktiengesellschaft
SIEGY
$62.27 (2.32%) $1.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.